Virpax Announces Pricing of $2.25 Million Public Offering
Summary
The Series A-2 warrants will have an exercise price of $1.35 per share, will be exercisable immediately, and will expire eighteen months from the initial issuance date.The closing of the offering is expected to occur on or about May 17, 2024, subject to the satisfaction of customary closing conditions.A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. When available, an electronic copy of the final prospectus may be obtained on the SECs website located at http://www.sec.gov and may also be obtained by contacting A.G.P./Alliance Global Partners at 590 Madison Avenue, 28th Floor, New York, NY 10022, by telephone at (212) 624-2060, or by email at prospectus@allianceg.com.This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax has competitive cooperative research and development agreements (CRADAs) for two of its prescription drug candidates, one with the National Institutes of Health (NIH) and one with the Department of Defense (DOD). These statements may be identified by the use of forward-looking expressions, including, but not limited to, expect, anticipate, intend, plan, believe, estimate, potential, predict, project, should, would and similar expressions and the negatives of those terms and include statements regarding the timing and completion of the proposed offering and the intended use of proceeds. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation.